1. Home
  2. HLVX

HLVX

HilleVax Inc.

Logo HilleVax Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 10:50am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Founded: 2020 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 826.5M IPO Year: 2022
Target Price: $28.50 AVG Volume (30 days): 129.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.04 EPS Growth: N/A
52 Week Low/High: $9.94 - $20.22 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: